Indeed, at present the predominant focus of PI3K inhibitor development is cancer, with small molecules targeting all Class I PI3K isoforms (either individually or non-selectively) currently in clinical trials, and Class II and Class III PI3K inhibitors being considered for future promise in this setting. The gene discussed is PIK3CB; the disease is cancer.